{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T12:17:51Z","timestamp":1793535471641,"version":"4.5.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,14]]},"DOI":"10.7759\/cureus.108824","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:30:42Z","timestamp":1778743842000},"source":"Crossref","is-referenced-by-count":3,"title":["Epistemic Barriers to Buprenorphine Access for Adolescents With Opioid Use Disorder"],"prefix":"10.7759","author":[{"given":"Arya","family":"Babul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohi","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Elmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Mahdavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000683","article-title":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 focused update: erratum","volume":"14","year":"2020","unstructured":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder. 2020 focused update: erratum. J Addict Med. 2020, 14:267. 10.1097\/ADM.0000000000000683","journal-title":"J Addict Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-1893","article-title":"Medication-assisted treatment of adolescents with opioid use disorders","volume":"138","year":"2016","unstructured":"Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics. 2016, 138.10.1542\/peds.2016-1893","journal-title":"Pediatrics"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2025.08.006","article-title":"Clinical practice guideline: assessment and treatment of adolescents and young adults with substance use disorders and problematic substance use (excluding tobacco)","volume":"65","author":"Rockhill CM","year":"2026","unstructured":"Rockhill CM, Ramtekkar U, Becker TD, et al.. Clinical practice guideline: assessment and treatment of adolescents and young adults with substance use disorders and problematic substance use (excluding tobacco). J Am Acad Child Adolesc Psychiatry. 2026, 65:105-38. 10.1016\/j.jaac.2025.08.006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref4","unstructured":"Guideline for the Clinical Management of Opioid Use Disorder. (2018). Accessed. December 15, 2025: https:\/\/tinyurl.com\/mv6dbht6."},{"key":"ref5","unstructured":"Extended\u2011release buprenorphine bulletin. British Columbia Centre on Substance Use (BCCSU). (2024). Accessed. December 15, 2025: https:\/\/tinyurl.com\/echab3kz."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2020.12.129","article-title":"Medication for adolescents and young adults with opioid use disorder","volume":"68","year":"2021","unstructured":"Medication for adolescents and young adults with opioid use disorder. J Adolesc Health. 2021, 68.632-6. 10.1016\/j.jadohealth.2020.12.129","journal-title":"J Adolesc Health"},{"key":"ref7","article-title":"Interventions for Substance Use Disorders in Adolescents: A Systematic Review","author":"Steele DW","year":"2020","unstructured":"Steele DW, Becker SJ, Danko KJ, et al.. Interventions for Substance Use Disorders in Adolescents: A Systematic Review. Agency for Healthcare Research and Quality (AHRQ), 2020."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2026.0041","article-title":"Comparative effectiveness of buprenorphine-naloxone and methadone for opioid overdose among youths","volume":"180","author":"Kleinman RA","year":"2026","unstructured":"Kleinman RA, Larney S, Sule NO, Ma C, Szatmari P, Kurdyak P. Comparative effectiveness of buprenorphine-naloxone and methadone for opioid overdose among youths. JAMA Pediatr. 2026, 180:577-9. 10.1001\/jamapediatrics.2026.0041","journal-title":"JAMA Pediatr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.574","article-title":"Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial","volume":"300","author":"Woody GE","year":"2008","unstructured":"Woody GE, Poole SA, Subramaniam G, et al.. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008, 300:2003-11. 10.1001\/jama.2008.574","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.10.1157","article-title":"Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial","volume":"62","author":"Marsch LA","year":"2005","unstructured":"Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, Brooklyn J. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005, 62:1157-64. 10.1001\/archpsyc.62.10.1157","journal-title":"Arch Gen Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/add.13363","article-title":"A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults","volume":"111","author":"Marsch LA","year":"2016","unstructured":"Marsch LA, Moore SK, Borodovsky JT, et al.. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction. 2016, 111:1406-15. 10.1111\/add.13363","journal-title":"Addiction"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001447","article-title":"The use of extended-release buprenorphine in the treatment of adolescent opioid use disorder: a case series","volume":"19","author":"Neptune A","year":"2025","unstructured":"Neptune A, Kaliamurthy S. The use of extended-release buprenorphine in the treatment of adolescent opioid use disorder: a case series. J Addict Med. 2025, 19:552-6. 10.1097\/ADM.0000000000001447","journal-title":"J Addict Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.0745","article-title":"Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014","volume":"171","author":"Hadland SE","year":"2017","unstructured":"Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014. JAMA Pediatr. 2017, 171:747-55. 10.1001\/jamapediatrics.2017.0745","journal-title":"JAMA Pediatr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2018.2143","article-title":"Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder","volume":"172","author":"Hadland SE","year":"2018","unstructured":"Hadland SE, Bagley SM, Rodean J, et al.. Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder. JAMA Pediatr. 2018, 172:1029-37. 10.1001\/jamapediatrics.2018.2143","journal-title":"JAMA Pediatr"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-018-0116-2","article-title":"Stigma associated with medication treatment for young adults with opioid use disorder: a case series","volume":"13","author":"Hadland SE","year":"2018","unstructured":"Hadland SE, Park TW, Bagley SM. Stigma associated with medication treatment for young adults with opioid use disorder: a case series. Addict Sci Clin Pract. 2018, 13:15. 10.1186\/s13722-018-0116-2","journal-title":"Addict Sci Clin Pract"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2023.6493","article-title":"Treating adolescent opioid use disorder in primary care","volume":"178","author":"Hadland SE","year":"2024","unstructured":"Hadland SE, Burr WH, Zoucha K, Somberg CA, Camenga DR. Treating adolescent opioid use disorder in primary care. JAMA Pediatr. 2024, 178:414-6. 10.1001\/jamapediatrics.2023.6493","journal-title":"JAMA Pediatr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-071147","article-title":"Buprenorphine treatment duration and adherence among youth and subsequent health outcomes","volume":"156","author":"Hadland SE","year":"2025","unstructured":"Hadland SE, Kimmel SD, Yan S, et al.. Buprenorphine treatment duration and adherence among youth and subsequent health outcomes. Pediatrics. 2025, 156:10.1542\/peds.2025-071147","journal-title":"Pediatrics"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108584","article-title":"Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults","volume":"132","author":"Welsh JW","year":"2022","unstructured":"Welsh JW, Dennis ML, Funk R, Mataczynski MJ, Godley MD. Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults. J Subst Abuse Treat. 2022, 132:108584. 10.1016\/j.jsat.2021.108584","journal-title":"J Subst Abuse Treat"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2022.2043335","article-title":"Attitudes and beliefs among Georgia addiction treatment staff about medication for opioid use disorder in adolescents, young adults, and adults: a multi-mixed methods study","volume":"48","author":"Welsh JW","year":"2022","unstructured":"Welsh JW, Mataczynski MJ, Passetti LL, Hunter BD, Godley MD. Attitudes and beliefs among Georgia addiction treatment staff about medication for opioid use disorder in adolescents, young adults, and adults: a multi-mixed methods study. Am J Drug Alcohol Abuse. 2022, 48:347-55. 10.1080\/00952990.2022.2043335","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2024.03.010","article-title":"Narrative review: revised principles and practice recommendations for adolescent substance use treatment and policy","volume":"64","author":"Welsh JW","year":"2025","unstructured":"Welsh JW, Dopp AR, Durham RM, et al.. Narrative review: revised principles and practice recommendations for adolescent substance use treatment and policy. J Am Acad Child Adolesc Psychiatry. 2025, 64:123-42. 10.1016\/j.jaac.2024.03.010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-025-01638-0","article-title":"Prevention and management of opioid use disorder and overdose in adolescents and young adults","volume":"27","author":"Welsh JW","year":"2025","unstructured":"Welsh JW, Krishnan SD, Terranella A. Prevention and management of opioid use disorder and overdose in adolescents and young adults. Curr Psychiatry Rep. 2025, 27:660-70. 10.1007\/s11920-025-01638-0","journal-title":"Curr Psychiatry Rep"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2505377","article-title":"Goals for opioid use disorder medications - protection, remission, and recovery","volume":"393","author":"McLellan AT","year":"2025","unstructured":"McLellan AT, Volkow ND. Goals for opioid use disorder medications - protection, remission, and recovery. N Engl J Med. 2025, 393:1253-5.","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.99631","article-title":"Medication based recovery in opioid use disorder: a clinical and epistemic imperative","volume":"17","author":"Babul A","year":"2025","unstructured":"Babul A, Mahdavi P, Hussain M, Janjua ZH, Babul N. Medication based recovery in opioid use disorder: a clinical and epistemic imperative. Cureus. 2025, 17:e99631. 10.7759\/cureus.99631","journal-title":"Cureus"},{"key":"ref24","unstructured":"Extended\u2011release vs sublingual buprenorphine for adolescent opioid use disorder (ERA) (NIH HEAL Initiative). (2026). Accessed. March 20, 2026: https:\/\/tinyurl.com\/jkncarcx."},{"key":"ref25","unstructured":"General clinical pharmacology considerations for pediatric studies of drugs, including biological products. Guidance for industry. (2022). Accessed. March 11, 2026: https:\/\/www.fda.gov\/media\/90358\/download."},{"key":"ref26","unstructured":"Pediatric study plans. content of and process for submitting initial pediatric study plans and amended initial pediatric study plans guidance for industry. (2020). Accessed: March 20, 2026: https:\/\/www.fda.gov\/media\/86340\/download."},{"key":"ref27","unstructured":"ICH E11(R1) addendum. clinical investigation of medicinal products in the pediatric population, guidance for industry. (2018). Accessed: March 20, 2026: https:\/\/www.fda.gov\/media\/101398\/download."},{"key":"ref28","unstructured":"Pediatric drug development. regulatory considerations - complying with the pediatric research equity act and qualifying for pediatric exclusivity under the best pharmaceuticals for children act. Guidance for industry. (2023). Accessed: March 20, 2026: https:\/\/www.fda.gov\/media\/168201\/download."},{"key":"ref29","unstructured":"Sublocade (buprenorphine extended-release) injection, for subcutaneous use. (2025). Accessed. March 7, 2026: https:\/\/tinyurl.com\/35r5v258."},{"key":"ref30","unstructured":"Brixadi (buprenorphine extended-release) injection, for subcutaneous use. (2025). Accessed. March 7, 2026: https:\/\/tinyurl.com\/mxy4ux44."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2025.6113","article-title":"Naloxone and buprenorphine treatment for adolescent opioid overdose and opioid use disorder: a review","volume":"180","author":"Ball A","year":"2026","unstructured":"Ball A, Buresh C, Hadland SE. Naloxone and buprenorphine treatment for adolescent opioid overdose and opioid use disorder: a review. JAMA Pediatr. 2026, 180:441-8. 10.1001\/jamapediatrics.2025.6113","journal-title":"JAMA Pediatr"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1177\/08897077231179576","article-title":"National trends in buprenorphine treatment for opioid use disorder from 2007 to 2018","volume":"44","author":"Schuler MS","year":"2023","unstructured":"Schuler MS, Saloner B, Gordon AJ, Dick AW, Stein BD. National trends in buprenorphine treatment for opioid use disorder from 2007 to 2018. Subst Abus. 2023, 44:154-63. 10.1177\/08897077231179576","journal-title":"Subst Abus"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2025.108538","article-title":"Medication for opioid use disorder among adolescents entering specialty treatment for opioid use disorder and trends in the US, 2017-2022","volume":"173","author":"Boggis JS","year":"2026","unstructured":"Boggis JS, Sweeney T, Marsch LA, Marrero WJ, Feder KA, Moen EL. Medication for opioid use disorder among adolescents entering specialty treatment for opioid use disorder and trends in the US, 2017-2022. Addict Behav. 2026, 173:108538. 10.1016\/j.addbeh.2025.108538","journal-title":"Addict Behav"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2025.00240","article-title":"Fewer than 1 in 3 adolescents with past-year opioid use disorder received substance use treatment, 2022-23","volume":"44","author":"Cano M","year":"2025","unstructured":"Cano M, Hernandez N, Mendoza NS, Bagley SM. Fewer than 1 in 3 adolescents with past-year opioid use disorder received substance use treatment, 2022-23. Health Aff (Millwood). 2025, 44:1060-9. 10.1377\/hlthaff.2025.00240","journal-title":"Health Aff (Millwood)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108130","article-title":"Age disparities in six-month treatment retention for opioid use disorder","volume":"213","author":"Mintz CM","year":"2020","unstructured":"Mintz CM, Presnall NJ, Sahrmann JM, Borodovsky JT, Glaser PE, Bierut LJ, Grucza RA. Age disparities in six-month treatment retention for opioid use disorder. Drug Alcohol Depend. 2020, 213:108130. 10.1016\/j.drugalcdep.2020.108130","journal-title":"Drug Alcohol Depend"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/ebnurs-2018-103053","article-title":"Medication assisted therapy (MAT) for opioid use disorder (OUD) in youth improves outcomes and saves lives","volume":"23","author":"O'Malley P","year":"2020","unstructured":"O'Malley P. Medication assisted therapy (MAT) for opioid use disorder (OUD) in youth improves outcomes and saves lives. Evid Based Nurs. 2020, 23:77. 10.1136\/ebnurs-2018-103053","journal-title":"Evid Based Nurs"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2021.4606","article-title":"Access to medications for opioid use disorder and associated factors among adolescents and young adults: a systematic review","volume":"176","author":"Pilarinos A","year":"2022","unstructured":"Pilarinos A, Bromberg DJ, Karamouzian M. Access to medications for opioid use disorder and associated factors among adolescents and young adults: a systematic review. JAMA Pediatr. 2022, 176:304-11. 10.1001\/jamapediatrics.2021.4606","journal-title":"JAMA Pediatr"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.35416","article-title":"Clinician willingness to prescribe medications for opioid use disorder to adolescents in Indiana","volume":"7","author":"Aalsma MC","year":"2024","unstructured":"Aalsma MC, Bell LA, Schwartz K, et al.. Clinician willingness to prescribe medications for opioid use disorder to adolescents in Indiana. JAMA Netw Open. 2024, 7:e2435416. 10.1001\/jamanetworkopen.2024.35416","journal-title":"JAMA Netw Open"},{"key":"ref39","unstructured":"Principles of adolescent substance use disorder treatment. a research\u2011based guide. (2014). Accessed: March 4, 2026: https:\/\/tinyurl.com\/36wpw866."},{"key":"ref40","unstructured":"Medications for opioid use disorder. treatment improvement protocol (TIP). (2021). Accessed. March 4, 2026: https:\/\/tinyurl.com\/yddbs7tk."},{"key":"ref41","article-title":"Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence","year":"2009","unstructured":"Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. World Health Organization, Geneva; 2009."},{"key":"ref42","article-title":"Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach","year":"2021","unstructured":"Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring. Recommendations for a Public Health Approach. World Health Organization, Geneva; 2021."},{"key":"ref43","article-title":"Drug Misuse in Over 16s: Opioid Detoxification. Clinical Guideline","year":"2007","unstructured":"Drug Misuse in Over 16s. Opioid Detoxification. Clinical Guideline . National Institute for Health and Care Excellence., 2007."},{"key":"ref44","article-title":"Drug Misuse Prevention Review-research and Analysis","year":"2022","unstructured":"Drug Misuse Prevention Review-research and Analysis. Prevention Working Group, AMCD, 2022."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.3209","article-title":"Naloxone prescriptions among commercially insured individuals at high risk of opioid overdose","volume":"2","author":"Follman S","year":"2019","unstructured":"Follman S, Arora VM, Lyttle C, Moore PQ, Pho MT. Naloxone prescriptions among commercially insured individuals at high risk of opioid overdose. JAMA Netw Open. 2019, 2:e193209. 10.1001\/jamanetworkopen.2019.3209","journal-title":"JAMA Netw Open"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2021.10.005","article-title":"Naloxone and buprenorphine prescribing following US emergency department visits for suspected opioid overdose: August 2019 to April 2021","volume":"79","author":"Chua KP","year":"2022","unstructured":"Chua KP, Dahlem CH, Nguyen TD, et al.. Naloxone and buprenorphine prescribing following US emergency department visits for suspected opioid overdose: August 2019 to April 2021. Ann Emerg Med. 2022, 79:225-36. 10.1016\/j.annemergmed.2021.10.005","journal-title":"Ann Emerg Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph23030336","article-title":"Exploring the Italian experience with long-acting buprenorphine formulations (LAIB) for the treatment of opioid use disorder: a series of narrative interviews","volume":"23","author":"Ariano V","year":"2026","unstructured":"Ariano V, Costanzo AF, Ferrante G, et al.. Exploring the Italian experience with long-acting buprenorphine formulations (LAIB) for the treatment of opioid use disorder: a series of narrative interviews. Int J Environ Res Public Health. 2026, 23:336. 10.3390\/ijerph23030336","journal-title":"Int J Environ Res Public Health"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-025-13607-7","article-title":"Reduced need for inpatient care following introduction of long-acting injectable buprenorphine","volume":"25","author":"Gauffin E","year":"2025","unstructured":"Gauffin E, Marques Franca A, Pizzaro Ferrero E, et al.. Reduced need for inpatient care following introduction of long-acting injectable buprenorphine. BMC Health Serv Res. 2025, 25:1397. 10.1186\/s12913-025-13607-7","journal-title":"BMC Health Serv Res"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2026.1774410","article-title":"Association between extended-release buprenorphine adherence and reduced healthcare costs among insured patients with opioid use disorder","volume":"14","author":"Jerry M","year":"2026","unstructured":"Jerry M, Venkat D, Flynn C, Tran AT, Abdel-Sattar M, Mullen W, Lane C. Association between extended-release buprenorphine adherence and reduced healthcare costs among insured patients with opioid use disorder. Front Public Health. 2026, 14:1774410. 10.3389\/fpubh.2026.1774410","journal-title":"Front Public Health"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1874","article-title":"Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial","volume":"74","author":"Walsh SL","year":"2017","unstructured":"Walsh SL, Comer SD, Lofwall MR, et al.. Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial. JAMA Psychiatry. 2017, 74:894-902. 10.1001\/jamapsychiatry.2017.1874","journal-title":"JAMA Psychiatry"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1111\/add.15627","article-title":"Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings","volume":"117","author":"Dunlop AJ","year":"2022","unstructured":"Dunlop AJ, White B, Roberts J, et al.. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings. Addiction. 2022, 117:382-91. 10.1111\/add.15627","journal-title":"Addiction"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001520","article-title":"Transition to extended-release buprenorphine injectable within seven days for opioid use disorder treatment: a scoping narrative","volume":"19","author":"Siu JT","year":"2025","unstructured":"Siu JT, Lau A, Wong JS, Machado J, Azar P. Transition to extended-release buprenorphine injectable within seven days for opioid use disorder treatment: a scoping narrative. J Addict Med. 2025, 19:371-80. 10.1097\/ADM.0000000000001520","journal-title":"J Addict Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/dar.14005","article-title":"Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open-label, non-randomised trial of long-acting injectable buprenorphine treatment in Australian custodial settings","volume":"44","author":"White B","year":"2025","unstructured":"White B, Little S, Haber PS, Roberts J, Nolan E, Lintzeris N, Dunlop AJ. Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open-label, non-randomised trial of long-acting injectable buprenorphine treatment in Australian custodial settings. Drug Alcohol Rev. 2025, 44:640-8. 10.1111\/dar.14005","journal-title":"Drug Alcohol Rev"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial","volume":"178","author":"Lofwall MR","year":"2018","unstructured":"Lofwall MR, Walsh SL, Nunes EV, et al.. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018, 178:764-73. 10.1001\/jamainternmed.2018.1052","journal-title":"JAMA Intern Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight BR","year":"2019","unstructured":"Haight BR, Learned SM, Laffont CM, et al.. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019, 393:778-90. 10.1016\/S0140-6736(18)32259-1","journal-title":"Lancet"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001195","article-title":"Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis","volume":"40","author":"Andorn AC","year":"2020","unstructured":"Andorn AC, Haight BR, Shinde S, et al.. Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis. J Clin Psychopharmacol. 2020, 40:231-9. 10.1097\/JCP.0000000000001195","journal-title":"J Clin Psychopharmacol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.9041","article-title":"Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: a randomized clinical trial","volume":"4","author":"Lintzeris N","year":"2021","unstructured":"Lintzeris N, Dunlop AJ, Haber PS, et al.. Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: a randomized clinical trial. JAMA Netw Open. 2021, 4:e219041. 10.1001\/jamanetworkopen.2021.9041","journal-title":"JAMA Netw Open"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1111\/add.14636","article-title":"Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder","volume":"114","author":"Frost M","year":"2019","unstructured":"Frost M, Bailey GL, Lintzeris N, et al.. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Addiction. 2019, 114:1416-26. 10.1111\/add.14636","journal-title":"Addiction"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.27019","article-title":"Emergency department-initiated buprenorphine for opioid use disorder: a randomized clinical trial","volume":"335","author":"D'Onofrio G","year":"2026","unstructured":"D'Onofrio G, Herring AA, Hawk KF, et al.. Emergency department-initiated buprenorphine for opioid use disorder: a randomized clinical trial. JAMA. 2026, 335:948-60. 10.1001\/jama.2025.27019","journal-title":"JAMA"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1093\/epirev\/mxaa001","article-title":"Adherence to and retention in medications for opioid use disorder among adolescents and young adults","volume":"42","author":"Viera A","year":"2020","unstructured":"Viera A, Bromberg DJ, Whittaker S, Refsland BM, Stanojlovi\u0107 M, Nyhan K, Altice FL. Adherence to and retention in medications for opioid use disorder among adolescents and young adults. Epidemiol Rev. 2020, 42:41-56. 10.1093\/epirev\/mxaa001","journal-title":"Epidemiol Rev"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000035","article-title":"A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine\/naloxone clinic","volume":"8","author":"Matson SC","year":"2014","unstructured":"Matson SC, Hobson G, Abdel-Rasoul M, Bonny AE. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine\/naloxone clinic. J Addict Med. 2014, 8:176-82. 10.1097\/ADM.0000000000000035","journal-title":"J Addict Med"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2012.04.011","article-title":"Predictors of attrition with buprenorphine\/naloxone treatment in opioid dependent youth","volume":"37","author":"Warden D","year":"2012","unstructured":"Warden D, Subramaniam GA, Carmody T, et al.. Predictors of attrition with buprenorphine\/naloxone treatment in opioid dependent youth. Addict Behav. 2012, 37:1046-53. 10.1016\/j.addbeh.2012.04.011","journal-title":"Addict Behav"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2024.04.010","article-title":"Injectable buprenorphine: an opportunity to improve treatment access for youth with opioid use disorder","volume":"75","author":"Calihan JB","year":"2024","unstructured":"Calihan JB, Bagley SM. Injectable buprenorphine: an opportunity to improve treatment access for youth with opioid use disorder. J Adolesc Health. 2024, 75:13-4. 10.1016\/j.jadohealth.2024.04.010","journal-title":"J Adolesc Health"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.103848","article-title":"Barriers to buprenorphine prescribing for opioid use disorder among Louisiana family physicians: a pilot survey study with narrative review","volume":"18","author":"Pippin M","year":"2026","unstructured":"Pippin M. Barriers to buprenorphine prescribing for opioid use disorder among Louisiana family physicians: a pilot survey study with narrative review. Cureus. 2026, 18:e103848. 10.7759\/cureus.103848","journal-title":"Cureus"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1542\/pedsos.2024-000392","article-title":"Opioid use disorder medications among youth in primary care: subgroup analysis of the PROUD trial","volume":"1","author":"Chavez LJ","year":"2025","unstructured":"Chavez LJ, Yu O, Wartko PD, et al.. Opioid use disorder medications among youth in primary care: subgroup analysis of the PROUD trial. Pediatr Open Sci. 2025, 1:10.1542\/pedsos.2024-000392","journal-title":"Pediatr Open Sci"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3390\/children12070876","article-title":"Perspectives from systems-level key informants on optimizing opioid use disorder treatment for adolescents and young adults","volume":"12","author":"Yeh J","year":"2025","unstructured":"Yeh J, Modrowski C, Aguirre I, Portis S, Miranda R Jr, Pielech M. Perspectives from systems-level key informants on optimizing opioid use disorder treatment for adolescents and young adults. Children (Basel). 2025, 12:876. 10.3390\/children12070876","journal-title":"Children (Basel)"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2023.08.047","article-title":"Medications for opioid use disorder for youth: patient, caregiver, and clinician perspectives","volume":"74","author":"Buchholz C","year":"2024","unstructured":"Buchholz C, Bell LA, Adatia S, Bagley SM, Wilens TE, Nurani A, Hadland SE. Medications for opioid use disorder for youth: patient, caregiver, and clinician perspectives. J Adolesc Health. 2024, 74:320-6. 10.1016\/j.jadohealth.2023.08.047","journal-title":"J Adolesc Health"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2026.100417","article-title":"Statewide trends in access to medications for opioid use disorder (moud) among adolescents with opioid use disorders in Indiana","volume":"18","author":"Gupta S","year":"2026","unstructured":"Gupta S, Schwartz K, Bell LA, Siegal N, Aalsma MC. Statewide trends in access to medications for opioid use disorder (moud) among adolescents with opioid use disorders in Indiana. Drug Alcohol Depend Rep. 2026, 18:100417. 10.1016\/j.dadr.2026.100417","journal-title":"Drug Alcohol Depend Rep"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000861","article-title":"Therapy dose mediates the relationship between buprenorphine\/naloxone and opioid treatment outcomes in youth receiving medication for opioid use disorder treatment","volume":"16","author":"Hammond CJ","year":"2022","unstructured":"Hammond CJ, Kady A, Park G, Vidal C, Wenzel K, Fishman M. Therapy dose mediates the relationship between buprenorphine\/naloxone and opioid treatment outcomes in youth receiving medication for opioid use disorder treatment. J Addict Med. 2022, 16:e97-e104. 10.1097\/ADM.0000000000000861","journal-title":"J Addict Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2025.06.023","article-title":"Trends in U.S. adolescent and young adult overdose fatalities, 1999-2023","volume":"77","author":"Chen Y","year":"2025","unstructured":"Chen Y, Seiters H, Wang Z, Bell LA. Trends in U.S. adolescent and young adult overdose fatalities, 1999-2023. J Adolesc Health. 2025, 77:997-1000. 10.1016\/j.jadohealth.2025.06.023","journal-title":"J Adolesc Health"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.15620\/cdc\/20250305008","article-title":"Provisional Drug Overdose Death Counts","author":"Ahmad FB","year":"2026","unstructured":"Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional Drug Overdose Death Counts. National Center for Health Statistics, 2026. 10.15620\/cdc\/20250305008"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.6286","article-title":"Proportion of fentanyl reports in illicit drug seizures and opioid mortality","volume":"7","author":"Dahlen A","year":"2026","unstructured":"Dahlen A, Lei F, Agyabeng K, et al.. Proportion of fentanyl reports in illicit drug seizures and opioid mortality. JAMA Health Forum. 2026, 7:e256286. 10.1001\/jamahealthforum.2025.6286","journal-title":"JAMA Health Forum"},{"key":"ref73","article-title":"Opioid overdose deaths: national trends and variation by demographics and states","author":"Saunders H","year":"2026","unstructured":"Saunders H, Panchal N, Rudowitz R. Opioid overdose deaths: national trends and variation by demographics and states. KFF. 2026,","journal-title":"KFF"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2019.5183","article-title":"Receipt of addiction treatment after opioid overdose among medicaid-enrolled adolescents and young adults","volume":"174","author":"Alinsky RH","year":"2020","unstructured":"Alinsky RH, Zima BT, Rodean J, et al.. Receipt of addiction treatment after opioid overdose among medicaid-enrolled adolescents and young adults. JAMA Pediatr. 2020, 174:e195183. 10.1001\/jamapediatrics.2019.5183","journal-title":"JAMA Pediatr"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.2847","article-title":"Trends in drug overdose deaths among US adolescents, January 2010 to June 2021","volume":"327","author":"Friedman J","year":"2022","unstructured":"Friedman J, Godvin M, Shover CL, Gone JP, Hansen H, Schriger DL. Trends in drug overdose deaths among US adolescents, January 2010 to June 2021. JAMA. 2022, 327:1398-400. 10.1001\/jama.2022.2847","journal-title":"JAMA"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2312084","article-title":"The overdose crisis among U.S. adolescents","volume":"390","author":"Friedman J","year":"2024","unstructured":"Friedman J, Hadland SE. The overdose crisis among U.S. adolescents. N Engl J Med. 2024, 390:97-100. 10.1056\/NEJMp2312084","journal-title":"N Engl J Med"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.15620\/cdc\/174582","article-title":"Trends in death rates for leading methods of injury: United States, 2003-2023","author":"Curtin SC","year":"2025","unstructured":"Curtin SC. Trends in death rates for leading methods of injury: United States, 2003-2023. NCHS Data Brief. 2025, 10.15620\/cdc\/174582","journal-title":"NCHS Data Brief"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7348a2","article-title":"Detection of illegally manufactured fentanyls and carfentanil in drug overdose deaths - United States, 2021-2024","volume":"73","author":"Tanz LJ","year":"2024","unstructured":"Tanz LJ, Stewart A, Gladden RM, Ko JY, Owens L, O'Donnell J. Detection of illegally manufactured fentanyls and carfentanil in drug overdose deaths - United States, 2021-2024. MMWR Morb Mortal Wkly Rep. 2024, 73:1099-105. 10.15585\/mmwr.mm7348a2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7150a2","article-title":"Drug overdose deaths among persons aged 10-19 years - United States, July 2019-December 2021","volume":"71","author":"Tanz LJ","year":"2022","unstructured":"Tanz LJ, Dinwiddie AT, Mattson CL, O'Donnell J, Davis NL. Drug overdose deaths among persons aged 10-19 years - United States, July 2019-December 2021. MMWR Morb Mortal Wkly Rep. 2022, 71:1576-82. 10.15585\/mmwr.mm7150a2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1542\/hpeds.2025-008620","article-title":"Pediatric emergency department visits for opioid overdose in the United States","volume":"16","author":"Devlin G","year":"2026","unstructured":"Devlin G, Kanak M, Hall M, Tanaka D, Bohorquez J, Gribbons M, Chaudhari PP. Pediatric emergency department visits for opioid overdose in the United States. Hosp Pediatr. 2026, 16:143-50. 10.1542\/hpeds.2025-008620","journal-title":"Hosp Pediatr"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-021-00249-3","article-title":"Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems","volume":"16","author":"Bagley SM","year":"2021","unstructured":"Bagley SM, Chavez L, Braciszewski JM, et al.. Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems. Addict Sci Clin Pract. 2021, 16:46. 10.1186\/s13722-021-00249-3","journal-title":"Addict Sci Clin Pract"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2017.1399403","article-title":"Medication-assisted treatment for youth with opioid use disorder: current dilemmas and remaining questions","volume":"44","author":"Chang DC","year":"2018","unstructured":"Chang DC, Klimas J, Wood E, Fairbairn N. Medication-assisted treatment for youth with opioid use disorder: current dilemmas and remaining questions. Am J Drug Alcohol Abuse. 2018, 44:143-6. 10.1080\/00952990.2017.1399403","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001486","article-title":"Clinician perspectives on barriers and facilitators to providing medications for opioid use disorder for adolescents","volume":"19","author":"Ruth J","year":"2025","unstructured":"Ruth J, Wagner S, Aalsma MC, Adams ZW, Bell LA. Clinician perspectives on barriers and facilitators to providing medications for opioid use disorder for adolescents. J Addict Med. 2025, 19:693-700. 10.1097\/ADM.0000000000001486","journal-title":"J Addict Med"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1542\/hpeds.2022-006864","article-title":"A novel inpatient buprenorphine induction program for adolescents with opioid use disorder","volume":"13","author":"Trope LA","year":"2023","unstructured":"Trope LA, Stemmle M, Chang A, Bashiri N, Bazazi AR, Lightfoot M, Congdon JL. A novel inpatient buprenorphine induction program for adolescents with opioid use disorder. Hosp Pediatr. 2023, 13:e23-8. 10.1542\/hpeds.2022-006864","journal-title":"Hosp Pediatr"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000388","article-title":"Buprenorphine treatment for adolescents and young adults with opioid use disorders: a narrative review","volume":"12","author":"Borodovsky JT","year":"2018","unstructured":"Borodovsky JT, Levy S, Fishman M, Marsch LA. Buprenorphine treatment for adolescents and young adults with opioid use disorders: a narrative review. J Addict Med. 2018, 12:170-83. 10.1097\/ADM.0000000000000388","journal-title":"J Addict Med"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000898","article-title":"Effectiveness of and access to medications for opioid use disorder for adolescents and young adults: a scoping review","volume":"16","author":"McCarty D","year":"2022","unstructured":"McCarty D, Chan B, Buchheit BM, Bougatsos C, Grusing S, Chou R. Effectiveness of and access to medications for opioid use disorder for adolescents and young adults: a scoping review. J Addict Med. 2022, 16:e157-64. 10.1097\/ADM.0000000000000898","journal-title":"J Addict Med"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108494","article-title":"Effectiveness of medication for opioid use disorders in transition-age youth: a systematic review","volume":"132","author":"Becker SJ","year":"2022","unstructured":"Becker SJ, Scott K, Helseth SA, et al.. Effectiveness of medication for opioid use disorders in transition-age youth: a systematic review. J Subst Abuse Treat. 2022, 132:108494. 10.1016\/j.jsat.2021.108494","journal-title":"J Subst Abuse Treat"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001391","article-title":"Brief report on outpatient treatment of adolescent opioid use disorder","volume":"19","author":"Kaliamurthy S","year":"2025","unstructured":"Kaliamurthy S, Straton E, Kumar P, Carleen A. Brief report on outpatient treatment of adolescent opioid use disorder. J Addict Med. 2025, 19:230-2. 10.1097\/ADM.0000000000001391","journal-title":"J Addict Med"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.09.020","article-title":"Memantine improves buprenorphine\/naloxone treatment for opioid dependent young adults","volume":"156","author":"Gonzalez G","year":"2015","unstructured":"Gonzalez G, DiGirolamo G, Romero-Gonzalez M, Smelson D, Ziedonis D, Kolodziej M. Memantine improves buprenorphine\/naloxone treatment for opioid dependent young adults. Drug Alcohol Depend. 2015, 156:243-53. 10.1016\/j.drugalcdep.2015.09.020","journal-title":"Drug Alcohol Depend"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2024.01.012","article-title":"Early remission of opioid use disorder in an adolescent using buprenorphine extended - release subcutaneous injection: a case report","volume":"75","author":"Schmuhl KK","year":"2024","unstructured":"Schmuhl KK, Golec A, Ebersole AM. Early remission of opioid use disorder in an adolescent using buprenorphine extended - release subcutaneous injection: a case report. J Adolesc Health. 2024, 75:200-2. 10.1016\/j.jadohealth.2024.01.012","journal-title":"J Adolesc Health"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108149","article-title":"Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency","volume":"120","author":"Wenzel K","year":"2021","unstructured":"Wenzel K, Fishman M. Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency. J Subst Abuse Treat. 2021, 120:108149. 10.1016\/j.jsat.2020.108149","journal-title":"J Subst Abuse Treat"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1007\/s11121-025-01835-6","article-title":"Investing in interventions to prevent opioid use disorder in adolescents and young adults: start-up costs from NIDA's HEAL prevention initiative","volume":"26","author":"Kuklinski MR","year":"2025","unstructured":"Kuklinski MR, Gibbons BJ, Bowser DM, et al.. Investing in interventions to prevent opioid use disorder in adolescents and young adults: start-up costs from NIDA's HEAL prevention initiative. Prev Sci. 2025, 26:1045-55. 10.1007\/s11121-025-01835-6","journal-title":"Prev Sci"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2025.250217R1","article-title":"Do no harm? Rethinking urine drug screens in treatment of opioid use disorder","volume":"38","author":"Beliveau C","year":"2026","unstructured":"Beliveau C, Baca-Atlas M. Do no harm? Rethinking urine drug screens in treatment of opioid use disorder. J Am Board Fam Med. 2026, 38:974-6. 10.3122\/jabfm.2025.250217R1","journal-title":"J Am Board Fam Med"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001672","article-title":"Low-threshold buprenorphine: proposing the ideal service model to engage people with severe opioid use disorder","author":"Fox AD","year":"2026","unstructured":"Fox AD, Messmer SE, Hayes BT, Salisbury-Afshar E, Chatterjee A, Jakubowski AU. Low-threshold buprenorphine: proposing the ideal service model to engage people with severe opioid use disorder. J Addict Med. 2026, 10.1097\/ADM.0000000000001672","journal-title":"J Addict Med"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2026.101435","article-title":"Burden of overdoses among persons with opioid use disorder in the United States, 2025-2028: a simulation modeling study","volume":"56","author":"Nataraj N","year":"2026","unstructured":"Nataraj N, Chen Y, Stewart A, et al.. Burden of overdoses among persons with opioid use disorder in the United States, 2025-2028: a simulation modeling study. Lancet Reg Health Am. 2026, 56:101435. 10.1016\/j.lana.2026.101435","journal-title":"Lancet Reg Health Am"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/485779-epistemic-barriers-to-buprenorphine-access-for-adolescents-with-opioid-use-disorder","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:30:49Z","timestamp":1778743849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/485779-epistemic-barriers-to-buprenorphine-access-for-adolescents-with-opioid-use-disorder"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":95,"URL":"https:\/\/doi.org\/10.7759\/cureus.108824","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}